Skip to main content
. 2024 May 6;52(12):7225–7244. doi: 10.1093/nar/gkae319

Figure 8.

Figure 8.

PRMT5-dependent FXR1 preferentially targets oncogenes and alters its expression in HNSCC. (A) Kaplan–Meier plots of overall survival of stage HNSCC patients (n = 522) stratified by FXR1 and PRMT5 mRNA expression (SD > 1). The log-rank P value and the number of cases per group are shown. (B) Optimized multiplex immunofluorescence showing the expression of FXR1 and PRMT5 in human HNSCC tumor and normal adjacent tissue samples. DAPI and CD3 staining was done for the nucleus and tumor markers. (C) Model represents the methylation dependent regulation of FXR1 and its RNA targets to promote or inhibit the tumor cell proliferation.